Venetoclax Combined With Azactidine in the Treatment of ALAL

Exclusion Criteria

• •1. Patients who are allergic to the study drug or drugs with similar chemical structures.
• •2. Pregnant or lactating women, and women of childbearing age who do not want to practice effective methods of contraception.
• •3. Active infection.
• •4. Active bleeding.
• •5. Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a medical history within one year before enrollment.
• •6. Patients with mental disorders or other conditions whereby informed consent cannot be obtained and where the requirements of the study treatment and procedures cannot be met.
• •7. Liver function abnormalities (total bilirubin \> 1.5 times the upper limit of the normal range, ALT/AST \> 2.5 times the upper limit of the normal range or patients with liver involvement whose ALT/AST \> 1.5 times the upper limit of the normal range), or renal anomalies (serum creatinine \> 1.5 times the upper limit of the normal value).
• •8. Patients with a history of clinically significant QTc interval prolongation (male \> 450 ms; female \> 470 ms), ventricular heart tachycardia and atrial fibrillation, II-degree heart block, myocardial infarction attack within one year before enrollment, and congestive heart failure, and patients with coronary heart disease who have clinical symptoms and requiring drug treatment.
• •9. Surgery on the main organs within the past six weeks.
• •10. Drug abuse or long-term alcohol abuse that would affect the evaluation results.
• •11. Patients who have received organ transplants (excepting bone marrow transplantation).
• •12. Patients not suitable for the study according to the investigator's assessment.